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Exceptional Chemotherapy
Response in Metastatic Colorectal
Cancer Associated With
Hyper-Indel–Hypermutated
Cancer Genome and Comutation
of POLD1 and MLH1
abstract
Purpose A 73-year-old woman with metastatic colon cancer experienced a complete response to 
chemotherapy with dose-intensified irinotecan that has been durable for 5 years. We sequenced 
her tumor and germ line DNA and looked for similar patterns in publicly available genomic data 
from patients with colorectal cancer.
Patients and Methods Tumor DNA was obtained from a biopsy before therapy, and germ line 
DNA was obtained from blood. Tumor and germline DNA were sequenced using a commercial 
panel with approximately 250 genes. Whole-genome amplification and exome sequencing were 
performed for POLE and POLD1. APOLD1 mutation was confirmed by Sanger sequencing. The 
somatic mutation and clinical annotation data files from the colon (n = 461) and rectal (n = 171) 
adenocarcinoma data sets were downloaded from The Cancer Genome Atlas data portal and 
analyzed for patterns of mutations and clinical outcomes in patients with POLE- and/or POLD1-
mutated tumors.
Results The pattern of alterations included APC biallelic inactivation and microsatellite in-
stability high (MSI-H) phenotype, with somatic inactivation of MLH1 and hypermutation 
(estimated mutation rate > 200 per megabase). The extremely high mutation rate led us to 
investigate additional mechanisms for hypermutation, including loss of function of POLE. POLE 
was unaltered, but a related gene not typically associated with somatic mutation in colon cancer, 
POLD1, had a somatic mutation c.2171G>A [p.Gly724Glu]. Additionally, we noted that the high 
mutation rate was largely composed of dinucleotide deletions. A similar pattern of hyper-
mutation (dinucleotide deletions, POLD1 mutations, MSI-H) was found in tumors from The 
Cancer Genome Atlas.
Conclusion POLD1 mutation with associated MSI-H and hyper-indel–hypermutated cancer 
genome characterizes a previously unrecognized variant of colon cancer that was found in this 
patient with an exceptional response to chemotherapy.
INTRODUCTION
A 73-year-old white woman presented with ab-
dominal pain, fatigue, and weight loss. Her hemo-
globin was 7 g/dL. Colonoscopy showed a cecal
mass, andbiopsy showed invasive adenocarcinoma.
She had blood transfusions, with an appropriate
increase in her hemoglobin. Her medical history
was significant for back surgery, depression, di-
verticulitis, hyperlipidemia, hypothyroidism, and
osteoporosis. Medications received were alendro-
nate, escitalopram, levothyroxine,androsuvastatin.
Familyhistorywas significant foradaughterhaving
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appearing andwithout any palpable lymphadenop-
athy, mass, or hepatosplenomegaly. Laboratory
findings were notable for hemoglobin 11.2 g/dL
(mean corpuscular volume, 75 fL), carcinoem-
bryonic antigen 2.2 ng/mL (reference range, 0 to
3.4 ng/mL), and total bilirubin 0.3 mg/dL. Com-
puted tomography (CT; Fig 1) showed diffuse
lymphadenopathy (para-aortic lymph node,
2.6 3 1.6 cm; portocaval lymph node, 3.1 3
2.9 cm), bilobar liver metastases (segment 4B le-
sion, 1.93 1.8 cm; segment 6 lesion, 2.13 2.6 cm),
and a cecal mass measuring 4.8 3 6 cm.
She enrolled in a genotype-guided dosing study of
FOLFIRI (fluorouracil [FU], leucovorin, and iri-
notecan) plus bevacizumab (ClinicalTrials.gov
identifier NCT01183494). The objective of this
studywas to define themaximum-tolerated dose of
irinotecan in FOLFIRI plus bevacizumab as first-
line therapy in metastatic colorectal cancer, with
dosing of irinotecan based onUGT1A1 genotype.1
Her UGT1A1 genotype was *1/*28, and she
was assigned to receive irinotecan at a dose of
310 mg/m2 intravenously (IV), 72% higher than
the standard dose of 180 mg/m2. She received
standard doses of the other drugs: FU 400 mg/m2
IV bolus, then 2,400 mg/m2 IV over 46 hours;
leucovorin200mg/m2IV;andbevacizumab5mg/kg
IV. After her first dose, she was hospitalized with
grade 3 neutropenia and grade 3 diarrhea. Her
seconddosewas delayed1week, and the irinotecan
dose was reduced to 233 mg/m2. She continued to
receive chemotherapy once every 2 weeks with no
additional grade 3 adverse events.
She experienced a complete response (CR) to
chemotherapy. CT after four doses showed a par-
tial response by RECIST,2 with a 44% reduction
in target lesions. She had additional reductions
after eight and12doses.After 14doses, she elected
to discontinue treatment and continued to un-
dergo surveillance CT scans (initially once every
3 months). Eventually, the liver lesions were no
longer visible, and all lymph nodes were smaller
BAFig 1. Selected imagesfrom (A) baseline
(pretreatment, 2010) and
(B) most recent (post-
treatment, 2015) computed
tomography scans for this
patient. Arrows indicate
liver metastases (upper
image) and primary tumor
in the cecum (lower image).
than 1 cm in short-axis dimension. Her most
recent CT, 53 months after discontinuing ther-
apy, showedno evidence of disease (Fig 1), andher
CEA has remained within normal limits. A colo-
noscopy was attempted 29 months after discon-
tinuing therapy but was incomplete because of
severe diverticulosis in the sigmoid colon that
caused narrowing and looping of the scope. Clin-
ically, she is doingwell and is active.On thebasis of
her durable CR to chemotherapy, she was able to
enter a clinical protocol to characterize the mo-
lecular alterations of her cancer.
PATIENTS AND METHODS
Tumor from the colonoscopic biopsy and a com-
parative normal sample (a single acid citrate dex-
trose tube of blood) were obtained and analyzed
according to procedures outlined in theUniversity
of North Carolina (UNC) Institutional Review
Board–approved protocol (ClinicalTrials.gov
identifier NCT01457196; UNCseq LCCC1108),
andclinical datawereobtainedaccording toHealth
Insurance Portability and Accountability Act stan-
dards. DNA from tumor and normal samples were
processed through the usual LCCC1108 produc-
tion pipeline of targeted capture sequencing as
described previously, with a modification for
small-volume input of less than1mgof input tumor
DNA.3 Briefly, tumor and normal samples were
sequenced using commercial protocols (Agilent
SureSelect custom targeted panel of approximately
250 genes; Santa Clara, CA) and the Illumina
HiSeq platform (San Diego, CA) in either single-
or paired-end format of 75 and 100 bases per end.
Averagedepth of coverage for target sequenceswas
665 reads in the tumor sample and 293 reads in the
germline sample. Raw sequencing images were
converted to FASTQ file format using Illumina
CASAVA software (version 1.8.2; http://support.
illumina.com/sequencing/sequencing_software/
casava.html). The sequence reads were aligned to
the genome using the bwamem algorithm (version
0.7.4; https://sourceforge.net/projects/bio-bwa/)
with the default parameters. Realignment was per-
formed simultaneously for tumor and normal pairs
using ABRA (version 0.46; https://github.com/
mozack/abra)with thedefault parameters.Variants
were called using FreeBayes (https://github.com/
ekg/freebayes) andsomaticmutationsusingStrelka
(http://strelka@ftp.illumina.com/). Copy number
assessments were performed using custom soft-
ware. Quality statistics were generated with Picard
(https://broadinstitute.github.io/picard/) and in-
cluded measures of fragment length, sequence
content, alignment, capture bias and efficiency,
coverage, and variant call metrics. Final somatic
calls were filtered to require a Strelka-assigned
quality of at least 30. All variants were annotated
in their gene-specific context usingSnpEff (version
3.1; http://snpeff.sourceforge.net/download.html)
and crossed with COSMIC and internal databases
that captured the information from the UNC
Clinical Committee for Genomic Research.3
To search for additional mutations in POLE and
POLD1, remaining tumor DNA was subjected to
whole-genome amplification using the REPLI-g
FFPE kit (QIAGEN Science, Germantown, PA)
according to themanufacturer’s technical notes for
low-input tumor. Whole-exome sequencing was
performed, and the identical informatics pipeline
was applied.
Focal validation of the POLD1 mutation was per-
formed on the whole-genome–amplified DNA us-
ing Sanger sequencing. Primers were designed to
flankexons18and26ofPOLD1andexon6ofPOLE:
POLD1 exon 18: 59-GCATGATTCTCTC-
CCCGACAG-39 (forward) and 59-CTGCCCTG-
GGCCCATCTCA-39 (reverse); POLD1 exon 26:
59-CCGGGAGTCTGAGCTGTATC-39 (for-
ward) and 59-CAGGGTCGGGACATGGCA-39
(reverse); andPOLE exon6: 59-CTCTTGAACCA-
ATGAGCGTGA-39 (forward) and 59-GTCGTT-
CTGAACCGCTGATG-39 (reverse). Polymerase
chain reaction amplification and Sanger sequencing
wereperformedusingapreviouslyvalidatedprotocol
within theUNCHospitalsMolecularGeneticsLab-
oratory (Chapel Hill, NC).
The somaticmutation andclinical annotationdata
files from the colon (n = 461) and rectal (n = 171)
adenocarcinoma data sets were downloaded from
The Cancer Genoma Atlas (TCGA) data portal.4
Of these 632 patient cases, 430 (colon, n = 330;
rectum, n = 99; unknown, n = 1) contained both
somatic mutation and clinical annotation data
points. The demographic and clinical character-
istics of the 430 patient cases are summarized in
Appendix Table A1. For each patient case, the
nonsilent somatic mutations and indels were de-
termined from the combined colorectal somatic
mutation file. Statistical tests betweengroupswere




A colonoscopic biopsy (2.1 3 0.3 3 0.3 cm in
aggregate) provided the only tumor tissue avail-
able. A hematoxylin and eosin section was made
from the residual tumor block (Fig 2), and the
remainder was entirely sectioned for the purpose
of obtaining DNA. The tumor was confirmed to
be amoderately differentiated adenocarcinomaby
study pathologists, and the percentage of tumor
nuclei was estimated at 60%. The sequencing
quality was acceptable for analysis per protocol
standards as characterized by inspection library
traces from theAgilentTape station, total number
of reads (. 27million unique reads aligned), peak
at150bpandnormaldistribution, andmean target
coverage of 1,534 reads.
On initial review of somatic variants (which were
not germline variants), themutational spectrumof
the tumor was consistent with known patterns for
colorectal cancer, including inactivating muta-
tions in APC and an activating mutation in
PIK3CA.5 An inactivatingmutationwas also noted
inMLH1, a gene associated with a subset of colon
cancers demonstrating the microsatellite instabil-
ity high (MSI-H) phenotype. Supporting the
MSI-H phenotype was the large number of mu-
tations observed in the tumor sample, with an
estimated mutation rate of more than 200 muta-
tions permegabase of captured sequence (. 1,000
mutations in the approximately 5 MB of targeted
sequence). Select protein-coding mutations in
genes previously associated with colon cancer
are listed in Table 1.
Review of the mutant allele fractions of APC and
PIK3CA was potentially informative as to the
nature of the tumor genome. Fifty-three percent
of the bases detected at position 1489 of APC
contained the inactivating allele. By contrast, only
28% of the bases of PIK3CA at position 1047 had
the activating allele. An additional two mutations
inAPCwere observed to have approximately 25%
mutant allele frequency.One interpretation of the
data is that the specimen consisted of nearly 100%
tumor nuclei in a genome that was tetraploid. In
such a case, there might have been an initial APC
Fig 2. (A) Low- and
(B) high-resolution images
of tumor biopsy sample






Percentage of tumor nuclei
was estimated at 60%.
mutation in 1489 followed by genome doubling,
resulting in two mutant alleles and two wild-type
alleles. This event was followed by independent
separatemutations, resulting in 25%mutant allele
fractions and complete loss of functional APC.
The mutation in PIK3CA, as well as most of the
more than 1,000 mutations, occurred after ge-
nome doubling, because the most common mu-
tant allele fractions were approximately 25%.
Tumor evolution in this manner suggests a mech-
anism by which a cell with so many mutations
might remain viable by offering four alleles to
retain at least one functional form of the gene.
Despite the large number ofmutations, the cancer
genome remained structurally intact (Fig 3). Ge-
nomes without such copy-number changes are
uncommon, with nearly every colon cancer dem-
onstrating amplifications or deletions.7 The only
evidence of genome instability in this patient case
involved low-level gains of chromosomes 17 and
19 and perhaps loss of a portion of chromosome
13. If the supposition of a tetraploid genome is
correct, these events might best be explained by
loss or gain of an additional chromosome from an
average copy of four alleles. Interestingly, it has
been suggested that tumors that retain wild-type
TP53 and/or are of the MSI-H phenotype are
more likely to have a stable genome configuration,
such as we saw in our patient case.8,9 In our patient
case, despite the large number of mutations, no
evidence for TP53mutation was detected. This is
also consistent with the observation that the fre-
quency of TP53 mutations is lower in MSI-H
tumors.10
Although the MSI-H phenotype with hypermu-
tation in association with MLH1 alteration is an
established entity,10 the overall number of muta-
tions in this patient case was particularly striking,
leading us to ask whether any additional alter-
ations might play a role. Specifically, we queried
whether previously reported mutations in POLE
might be present.8 Because POLE was not in-
cluded in the original hybrid capture set, the
remaining DNA was submitted for whole-
exome sequencing, and no POLE mutation
was detected. Next, we considered the possibility
of a somatic mutation in another gene in the
same family, POLD1, because germline muta-
tions in POLD1 have been described as drivers
of colorectal cancer.11,12 Interrogation of the
POLD1 sequence revealed a somatic c.2171G.A
[p.Gly724Glu] mutation (Fig 4) that was subse-
quently validated by Sanger sequencing. This
particular mutation has not previously been re-
ported as a driver mutation in colorectal cancer,
but it is in close proximity to a cluster of previously
reported mutations in the DNA polymerase B
domain.11,12
Analysis of TCGA Data
To put the findings from our patient case into the
context of prior reports in colorectal cancer, we
turned to TCGA.8 TCGA confirmed the pres-
ence of somatic POLE mutations in 31 patient
cases (7.2%). POLD1mutations were observed in
17 patient cases (4.0%), just below the 5% rate
targeted for detection in TCGA. Five cancers
(1.2%) contained both POLE and POLD1 muta-
tions. When examining the distribution of non-
silent somatic mutations in POLE, we observed
that they were spread across all coding domains of
the gene; however, mutations in the DNA poly-
merase B exonuclease domain were strongly
Table 1. Select Protein-Coding Mutations in Patient’s Primary Tumor by Whole-Genome Sequencing
Gene Chromosome Coordinate cDNA Protein Effect MAF (%) Q COSMIC6
MLH 1 3 37089122 c.1852_1854delAAG p.Lys618del Codon deletion 54 366 3
TGFBR2 3 30691871 c.383delA p.Lys128fs Frameshift 54 NA* 5
APC 5 112175755 c.4464_4465insT p.Leu1489fs Frameshift 53 517 44
NRAS 1 115252312 c.328C.T p.Pro110ser Nonsynonymous coding 33 436 0
PIK3CA 3 178952085 c.3140A.G p.His1047Arg Nonsynonymous coding 28 346 1,906
APC 5 112170693 c.1789G.A p.Ala597Thr Nonsynonymous coding 28 380 1
APC 5 112179035 c.7748delA p.Ala2584fs Frameshift 25 376 1
ARID1A 1 27100175 c.3977delC p.Pro1326fs Frameshift 21 284 1
TOP1 20 39657712 c.5G.A p.Ser2Asn Nonsynonymous coding 15 45 0
TOP1 20 39721171 c.674C.T p.Pro225Leu Nonsynonymous coding 10 491 0
NOTE. Protein-coding mutations selected from 1,192 somatic mutations identified; organized top to bottom by MAF.
Abbreviations: COSMIC, Catalogue of Somatic Mutations in Cancer; MAF, mean allelic frequency; NA, not applicable; Q, 210 3 log10 (probability of sequencing error).
*Q score not defined for this deletion event.
associatedwith ultra-highmutation rates (. 2,000
mutations; Fig 4, top). Nonsilent somatic muta-
tions in POLD1 were located mainly in the exo-
nuclease and polymerase B domains (Fig 4,
bottom).Wethen looked for associationsofPOLE
and POLD1mutations with both overall mutation
rate and the pattern of hyper-indel hypermutation
seen in our patient case (Fig 5A). This inquiry
revealed a divergence in patterns between POLE
and POLD1 mutations. Colorectal cancers with
ultra-high mutation rates (. 2,000 nonsilent so-
maticmutations) invariably exhibitedmutations in
POLE, but not all POLE mutations were associ-
ated with ultra-high mutation rates. Strikingly,
however, the fraction of indels among all muta-
tions in these patient cases remained low, gener-
ally below 5%. By contrast, cancers with POLD1
mutations were not associated with ultra-high
mutation rates, although the median number of
nonsilent mutations was much higher (893 muta-
tions) than the median for the entire data set (134
mutations). Consistent with our report, POLD1
mutants were associated with a high rate of indels
(17% of all mutations). All POLD1 mutations
occurred in the set of tumors described as MSI-
H. By contrast, there were 52MSI-H tumors that
did not have POLD1 mutations. Cancers with
POLE and/or POLD1 mutations generally were
hypermutated, with only seven patient cases
(1.6%) having fewer than 200 nonsilent somatic
mutations.
We considered the possibility that, because the set
of samples being considered included those with
the highest mutation rates, mutations of POLD1
might simply occur by random chance. The prob-
ability of detecting 15 POLD1mutations in these
samples was, 0.001 (Fisher’s exact test). Further
arguing against chance alone, we noted that
POLD1 mutations were not observed in any of
thepatient casesofPOLEultramutated tumorsbut
rather uniquely in patients with MSI-H pheno-
type with high numbers of indels. Finally, the
clustering ofmutationswithin theDNApolymer-
ase B domain of the gene supports the hypothesis
that these are not random mutations.
Chromosome
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results from the primary
tumor of this patient. Red
lines are fitted CNV
numbers obtained from
sequenced variants (dots on
the plot). Chromosome
8 (chr8) and chr19 are
magnified to illustrate no
significant CNVs (chr8)
and low-level gains (chr19).
Because POLD1 mutations were associated with
MSI-H phenotype, we considered the possibility
that these mutations were a passenger event con-
fined to the biology of MSI-H cancers. Compar-
ison of indel rate in MSI-H cancers on the basis
of POLD1 mutation status revealed that MSI-H
cancers with POLD1 mutations exhibited app-
roximately 60%more indels thanMSI-H cancers
without POLD1mutations (P, .03; Fig 5B). Not
surprisingly, hypermutated cancers exhibited a
much higher indel rate than nonhypermutated
cancers (P , .001; Fig 5C). However, POLE-
hypermutated cancers exhibited approximately
50% fewer indels than hypermutated cancers
without POLE mutations (P , .001; Fig 5C).
DISCUSSION
CRs to chemotherapy have been described pre-
viously in patients with colorectal cancer. A recent
meta-analysis of chemotherapy plus bevacizumab
reported aCR rate of 2.4%based on aggregate data
from seven randomized controlled trials.13 Because
these responses are infrequent, and many of them
occurred in the era before genomic profiling of
tumors, the links between tumor genomics and
exceptional responses are unclear. Having
observed a CR to FOLFIRI and bevacizumab that
has been durable for 5 years in the patient case
presented here, sequencing of tumor and germline
DNA was undertaken to search for alterations
associated with this exceptional response. A similar
strategy is being used in the exceptional responders’
protocol sponsored by the National Cancer Insti-
tute (ClinicalTrials.gov identifier NCT02243592).
TCGANetwork reported on the molecular char-
acterization of human colon and rectal cancers in
2012.6 Tumors were classified as nonhypermu-
tated versus hypermutated, with the latter having
mutations in more than 12 of 106 bases and a
median of 728 mutations on exome sequencing.
Hypermutated tumors were more likely to orig-
inate in the right colon and could be further
classified into two types: a majority with MSI-H
that had relatively fewermutations, and aminority
without MSI-H that had relatively more muta-
tions (ultramutated).MSI-H tumors typically had
hypermethylation and MLH1 silencing, whereas
hypermutated tumors without MSI-H typically
had somatic mutations in one or more mismatch-
repair genes and/or POLE. Right-sided colon
cancers were recently reported to be associated
with worse prognosis compared with left-sided
colon cancers in a systematic review and meta-
analysis,14 but it is not clear whether the same
would be true for hypermutated right-sided colon
cancers.
DNA polymerases e (POLE) and d (POLD1) are
the two main enzymes involved in human DNA
replication. Germline and somatic mutations
in the exonuclease (proofreading) domains of
POLE and POLD1 are associated with ultramu-
tated colorectal and endometrial cancers.12,15
Whole-genome sequencing in our patient case
showed a hypermutated (but not ultramutated)
phenotype in this right-sided tumor with many
indels including a codon deletion ofMLH1, so the
decision was made to pursue whole-exome se-
quencing to search for additional mutations in
POLE or POLD1. We identified and validated a
POLD1 mutation in this patient’s tumor. Impor-
tantly, this mutation was not in the exonuclease
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Fig 4. Lollipop plots
showing mutations in (A)
POLE and (B)POLD1 from
The Cancer Genome Atlas
(TCGA), as well as (B) the
mutation in POLD1 from
our patient. Somatic
mutations identified in the
colorectal TCGA data set
were broadcast onto the












function found on epsilon
catalytic subunit of DNA
polymerase; zf-…, zf-C4pol
(C4-type zinc-finger of
DNA polymerase delta). All
domains were annotated
from the Pfam database.
MSI-H, microsatellite
instability high.
Analysis of TCGA confirmed that the observed
phenotype was similar to other tumors with
POLD1 mutations. We found that POLD1-mu-
tated tumors have relatively greater numbers of
indels than POLD1 wild-type tumors, including
those with POLE mutations. To our knowledge,
this is a pattern that has not previously been
reported in the literature.
Two previous studies have attempted to relate
POLE mutations to colorectal cancer outcomes.
In a population-based cohort with microsatellite-
stable stage I to IV colorectal cancer, Stenzinger
et al16 reported a trend toward shorter survival for
patients with POLE mutations compared with
their counterparts without POLE mutations.
Along the same lines, there was a statistically
significantly increased mortality for patients with
stage III to IV colorectal cancer receiving chemo-
therapy with POLE mutations compared with
their counterparts without POLE mutations.16
In contrast, Domingo et al17 recently reported
thatPOLEmutations were associatedwith a lower
risk of recurrence compared with microsatellite-
stable stage II to III colorectal cancers, with cor-
relative data suggesting that these tumors were
more immunogenic. Rizvi et al18 showed that
higher nonsynonymous mutation burden was as-
sociated with markers of immunogenicity and
improved outcomes with programmed death-1
blockade in non–small-cell lung cancer. In our
analyses of data from TCGA, there were no sta-
tistically significant differences in survival based
on overall mutation status, POLEmutation status,
POLD1 mutation status, or combined POLE and
POLD1 mutation status (Appendix Fig A1).
An important limitation of this study is that it was
impossible to isolate the genomic alterationsmost
important in this patient’s exceptional response. It
is reasonable to postulate that the POLD1 muta-
tion led to the somatic codon deletion of MLH1
and the MSI-H phenotype. Analysis of CALGB
89803 suggested that patients with MSI-H colon
cancer had improved disease-free survival in a
study of FU plus leucovorin versus FOLFIRI as
adjuvant therapy for stage II to III disease.19 If the
mutations in topoisomerase I (TOP1) are gain-of-
function mutations and/or result in gene amplifi-
cation (their function is unknown), this might
increase sensitivity to irinotecan (a topoisomerase
I–interacting drug), because higher copy numbers
of this gene have been linked to irinotecan sensi-























































































POLE and POLD1 mutant
*P < .03
*P < .001
Fig 5. (A) Nonsilent
mutations versus insertions
or deletions (indels) for
POLE- and POLD1-




indels were calculated for
each colorectal tumor from
the TCGA data set
(n = 430). Tumors with
somaticmutations in POLE
(blue), POLD1 (gold), or









from TCGA. Number of
indel was calculated for the
67MSI-H tumors from the
colorectal TCGA data set.
MSI-H tumors that also
had POLD1 somatic
mutations exhibited more




indels, n = 230; mean
POLD1 WT indels,
n = 144). (C) Indels among
hypermutated (n = 50),
nonhypermutated
(n = 356), and POLE-
hypermutated (n = 24)
tumors from TCGA (total,
n = 430; mean
hypermutated indels,
n = 176; mean
nonhypermutated indels,
n = 6; mean POLE-
hypermutated indels,
n = 91). (*) Two-sided t test.
mutation burden and immunogenicity,18 it is also
possible that chemotherapy induced an endoge-
nous immune response to a variety of neoantigens
in this patient’s cancer.
In conclusion, an exceptional response in a pa-
tient with metastatic colorectal cancer to FOL-
FIRI plus bevacizumab led us to identify a
somatic mutation in POLD1. In TCGA, POLD1
mutants have a hypermutated phenotype with a
large number of indels comparedwith their wild-
type and POLE-mutant counterparts. This study
is hypothesis generating and supports the se-
quencing of POLE and POLD1 in patients with
exceptional responses to better understand the
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APPENDIX
Table A1. Demographic and Clinical Characteristics of Patient Cases in Analyses From
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Fig A1. Kaplan-Meier
survival curves for cases of
colorectal cancer from The
Cancer Genome Atlas with
survival and somatic
mutation data. Survival
curves were generated on
different data subsets based
on (A) hypermutation
status (hypermutated,
n = 78 [deaths, n = 12];
nonhypermutated, n = 305
[deaths, n = 70]; log-rank
x2 = 0.5020; Wilcoxon
x2 = 0.7898), (B) POLE
mutations (POLE mutated,
n = 32 [deaths, n = 5]; wild
type [WT], n = 450 [deaths,
n = 78]; log-rank x2 = 0.626;
Wilcoxon x2 = 0.8993), (C)
POLD1mutations (POLD1
mutated, n = 17 [deaths,
n = 6];WT, n = 465 [deaths,
n = 77]; log-rank
x2 = 0.0322; Wilcoxon
x2 = 0.1052), or (D)
combined POLE and
POLD1 mutations (POLE
andPOLD1mutated, n = 44
[deaths, n = 8];WT, n = 438
[deaths, n = 75]; log-rank
x2 = 0.9852; Wilcoxon
x2 = 0.7380). For all
analyses, survival was
capped at 60 months.
